The field of organ-on-a-chip has been in existence for 20 years, with the pace of commercialization increasing significantly in the past 5 years. CN Bio Innovations have commercialized single and multi-organ chips based on technology from the lab of Prof L. Griffith at M.I.T. Liver and liver disease models are an attractive target for organ-on-a-chip technologies owing to the relatively rapid dedifferentiation of primary liver cells in 2D culture. In this presentation I will discuss the development and commercialization of CN Bio Innovation’s LiverChip platform together with Quantum B our full viral life cycle model of Hepatitis B infection and look ahead to opportunities for multi-organ systems.
Advertisement
Recommended Videos
Video
It is important to identify the enzymes that significantly contribute to the metabolism of a drug candidate and to evaluate the potential of a drug candidate to be a victim or perpetrator. Knowing how a drug candidate is eliminated by the human body is important in understanding the potential for drug-drug interactions.
WATCH NOWLike what you just watched? You can find similar content on the communities below.
Drug DiscoveryTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
Advertisement